Skip to main content

Table 1 Clinical characteristics of the patients; 70 having the JIA diagnosis and 20 arthralgia

From: Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use

All patients

n = 90

Oligo

n = 33

Poly

n = 29

JSpA

n = 8

All JIA

n = 70

Arthralgia

n = 20

Age

10.2 ± 3.8

8.1 ± 3.5

11.8 ± 3.0

9.6 ± 3.9

8.7 ± 4.9

Female

25 (57%)

19 (43%)

0

44 (63%)

13 (65%)

ANA-Ab +

4 (12%)

6 (21%)

0

9 (13%)

1 (5%)

Anaemia

10 (30%)

9 (31%)

3 (38%)

22 (31%)

1 (5%)

HLA-B27 +

9 (27%)

6 (21%)

7 (88%)

22 (31%)

5 (25%)

Active disease

8 (24%)

9 (31%)

0

17 (24%)

0

NSAID +

15 (45%)

14 (48%)

5 (63%)

34 (49%)

12 (60%)

DMARD +

20 (61%)

20 (69%)

5 (63%)

45 (64%)

0

Biologicals +

3 (10%)

2 (7%)

0

5 (7%)

0

  1. JIA juvenile idiopathic arthritis
  2. Oligo juvenile oligoarthritis, Poly juvenile polyarthritis (RF-negative), JSpA juvenile spondyloarthritis (including enthesitis related arthritis)
  3. ANA-Ab antinuclear antibodies
  4. DMARD disease-modifying anti-rheumatic drug
  5. mainly methotrexate (MTX), other DMARDS: leflunomide, sulphasalazine (SSZ), hydroxychloroquine, cyclosporine A (CyA)
  6. - Ten patients had ≥1 DMARD (usually MTX + SSZ), one patient had CyA with SSZ
  7. NSAID non-steroidal anti-inflammatory drug